Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,275.00
+40.00 (1.24%)
Sep 19, 2025, 3:30 PM KST

Xcell Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
35,82344,384----
Upgrade
Enterprise Value
37,82438,298----
Upgrade
Last Close Price
3275.004065.00----
Upgrade
PS Ratio
24.1222.95----
Upgrade
PB Ratio
8.854.87----
Upgrade
P/TBV Ratio
10.565.17----
Upgrade
EV/Sales Ratio
25.4619.80----
Upgrade
Debt / Equity Ratio
1.400.632.730.690.383.54
Upgrade
Asset Turnover
0.150.140.090.050.100.05
Upgrade
Inventory Turnover
3.024.444.014.673.872.48
Upgrade
Quick Ratio
0.731.900.361.192.831.18
Upgrade
Current Ratio
1.042.140.521.392.931.29
Upgrade
Return on Equity (ROE)
-981.05%-165.90%-170.80%-67.53%-102.65%-
Upgrade
Return on Assets (ROA)
-66.83%-42.63%-43.01%-26.46%-18.88%-26.46%
Upgrade
Return on Capital (ROIC)
-88.50%-49.18%-48.12%-28.23%-24.84%-108.77%
Upgrade
Earnings Yield
-28.99%-21.50%----
Upgrade
FCF Yield
-25.42%-16.63%----
Upgrade
Buyback Yield / Dilution
-20.42%-13.14%-1.02%-5.71%-131.08%-107.45%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.